Mobile

A phase II/III, multi-center, randomized, 4-week, double-blind, parallel group, placebo and active-controlled trial of the safety and efficacy of RO4917838 vs. placebo in patients with an acute exacer...

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-021984-33

A phase II/III, multi-center, randomized, 4-week, double-blind, parallel group, placebo and active-controlled trial of the safety and efficacy of RO4917838 vs. placebo in patients with an acute exacerbation of schizophrenia

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

�Change in Positive and Negative Syndrome Scale (PANSS) total score [ Time Frame: from baseline to Day 28 ] [ Designated as safety issue: No ] � Safety: Incidence adverse events [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Critère d'inclusion

  • Acute Symptoms of Schizophrenia

Liens